Mechanistic Role of ALDOB K87 Lactylation in Pulmonary Hypertension

Study Background and Research Question

Pulmonary hypertension (PH) is a progressive, life-threatening vascular disorder characterized by occlusive arteriopathy, right ventricular failure, and limited responses to current vasodilator therapies. A mounting body of research suggests that pulmonary artery smooth muscle cell (PASMC) proliferation, migration, and phenotypic switching underlie vascular remodeling in PH. Recent investigations have highlighted the centrality of metabolic reprogramming—specifically, the shift from oxidative phosphorylation to aerobic glycolysis (the Warburg effect)—in driving these pathogenic changes. However, the molecular link between metabolic alterations and mitochondrial dynamics in PASMCs remained insufficiently understood.

The study by Yi et al. (2026) addresses this gap by investigating whether post-translational protein lactylation, particularly at lysine-87 of aldolase B (ALDOB), orchestrates mitochondrial fission and metabolic remodeling in PH, ultimately influencing PASMC behavior and vascular pathology.

Key Innovation from the Reference Study

The principal innovation of Yi et al.'s work lies in identifying and functionally characterizing ALDOB K87 lactylation as a critical driver of mitochondrial fragmentation and metabolic reprogramming in the context of PH. This study is among the first to demonstrate that nonhistone protein lactylation, previously recognized for its role in epigenetic regulation, directly modulates mitochondrial dynamics and cell phenotype via a lactate–ALDOB–DRP1 axis. The mechanistic connection established here provides a molecular basis for targeting metabolic-structural crosstalk in pulmonary vascular disease.

Methods and Experimental Design Insights

Yi et al. employed an integrative methodological framework combining lactylomic profiling, rodent PH models, and functional assays in hypoxic human PASMCs. Key techniques included:

• Lactylome sequencing: To identify global and site-specific lactylation changes under hypoxic conditions relevant to PH.
• Immunoprecipitation and mass spectrometry: For validating specific ALDOB K87 lactylation and assessing its abundance.
• Genetic manipulation: Use of lactylation-mimetic and non-lactylatable ALDOB mutants, alongside Sirtuin 1 (SIRT1) modulation, to dissect causal relationships.
• In vivo rodent PH models: To confirm the relevance of findings in animal models recapitulating human disease features.
• Cellular functional assays: PASMC proliferation, migration, and mitochondrial fission were quantified using established protocols, often involving growth factor stimulation and metabolic flux measurements.

This multipronged approach enabled the authors to attribute observed phenotypes specifically to ALDOB K87 lactylation and its downstream signaling.

Core Findings and Why They Matter

The reference study's core findings can be summarized as follows:

• ALDOB K87 lactylation is markedly increased in hypoxic PASMCs and in rodent models of PH, correlating with heightened glycolytic activity and lactate accumulation (Yi et al., 2026).
• Lactylated ALDOB recruits DRP1 to mitochondria: Mechanistically, ALDOB K87 lactylation facilitates DRP1 translocation by promoting sentrin/SUMO-specific peptidase 3 (SENP3)-mediated deSUMOylation of DRP1, thereby triggering mitochondrial fission.
• Enhanced mitochondrial fission drives PASMC proliferation and migration: These processes underpin vascular remodeling and PH progression.
• SIRT1 acts as a delactylase: SIRT1 downregulation in PH sustains pathological ALDOB lactylation, while genetic or pharmacological inhibition of lactylation attenuates disease phenotypes.
• Lactylation-mimetic ALDOB mutants exacerbate PH: These data indicate a direct, causal role for this post-translational modification in disease pathogenesis.

This study establishes a feedback loop wherein hypoxia-induced metabolic remodeling (increased glycolytic flux and lactate production) drives further lactylation, which in turn amplifies mitochondrial fragmentation and smooth muscle cell pathology.

Protocol Parameters

• Hypoxic PASMC culture: 1% O₂ exposure for 24–48 hours to mimic PH-relevant stress.
• Lactylation quantification: Immunoprecipitation of ALDOB followed by site-specific mass spectrometry.
• Functional assays: Cell proliferation assessed via EdU or BrdU incorporation; migration by Transwell assay; mitochondrial fission quantified by fluorescence microscopy and mitochondrial morphology metrics.
• Genetic manipulation: Lentiviral or plasmid-based expression of ALDOB K87 mutants (K87Q for lactylation mimic, K87R for non-lactylatable form).

Comparison with Existing Internal Articles

The insights from Yi et al. offer a refined mechanistic context to prior discussions of metabolic regulation and PASMC behavior. For example, the article "ALDOB K87 Lactylation Drives Mitochondrial Fission in PH" aligns with the reference study in identifying the lactylation-mitochondrial fission link, while "PDGF-BB, Murine Recombinant Protein: Mechanistic Insights and Metabolic Contexts" explores the interplay of growth factor signaling (such as PDGF-BB mitogen activity) with metabolic remodeling. Together, these resources underscore the importance of integrating cell proliferation assays with metabolic and mitochondrial endpoints when studying vascular remodeling in PH. Researchers utilizing murine recombinant PDGF-BB for cell proliferation assay with PDGF-BB or for modeling smooth muscle cell proliferation may find these mechanistic insights particularly relevant for experimental optimization.

Limitations and Transferability

While the study robustly implicates ALDOB K87 lactylation in PH pathogenesis, certain limitations warrant consideration. The majority of mechanistic data derive from hypoxic PASMCs and rodent PH models; extrapolation to human PH, especially across its heterogeneous etiologies, requires further validation. Additionally, the focus on ALDOB and DRP1 does not exclude the involvement of other metabolic or mitochondrial regulators in vascular remodeling. The translation of these findings to therapeutic intervention remains at a preclinical stage.

Research Support Resources

Researchers aiming to dissect PASMC proliferation and mitochondrial dynamics in the context of metabolic reprogramming can leverage PDGF-BB, murine recombinant protein (SKU P1048) for controlled stimulation of cell growth and pathway interrogation. This reagent, with confirmed batch-specific activity and high purity, is suitable for research use in proliferation and signaling assays, including those exploring the intersection of PDGFR-α and PDGFR-β signaling with metabolic and mitochondrial endpoints. For detailed workflows and troubleshooting, the resource "Applied Workflows with Murine Recombinant PDGF-BB in Cell Assays" offers protocol and optimization guidance for integrating growth factor stimulation with advanced metabolic and imaging readouts.